Neurogene (NGNE) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
3 Jun, 2026Opening remarks and agenda
Meeting called to order by the Executive Chair with board members, management, and external representatives present.
Inspector of Elections and Secretary roles assigned; meeting rules and agenda reviewed for orderly conduct.
Only stockholders of record as of April 7, 2026, were eligible to participate and vote.
Board and executive committee updates
Board members and senior management introduced, including Lead Independent Director and other directors.
Shareholder proposals
No shareholder proposals were submitted in accordance with advance notice bylaw provisions.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Neurogene
- NGN-401 pivotal data due H2 2027; 9 of 25 responders meet statistical success.NGNE
Stifel 2026 Healthcare Conference 2026 - All 10 Phase I/II patients gained milestones as the 12-month pivotal readout approaches.NGNE
3rd Annual Guggenheim Healthcare Innovation Conference - NGN-401 advances toward H2 2027 topline data, with cash runway into Q1 2029.NGNE
Q3 2026 - Gene therapy NGN-401 shows robust efficacy and safety in Rett syndrome, with pivotal data due 2027.NGNE
H.C. Wainwright 28th Annual Global Investment Conference - NGN-401 shows robust, durable efficacy and safety, advancing toward commercialization for Rett syndrome.NGNE
Corporate presentation - NGN-401 showed robust efficacy and safety, with cash runway into Q1 2029.NGNE
Q2 2026 - NGN-401's pivotal study nears completion, with 12-month data and US commercialization on track for 2026.NGNE
Guggenheim Securities Emerging Outlook: Biotech Summit 2026 - NGN-401 gene therapy enabled rapid, durable, multidomain gains with strong safety in Rett syndrome.NGNE
Study result - NGN-401 shows durable, multidomain benefits in Rett syndrome, with pivotal trial and launch prep underway.NGNE
Corporate presentation